CERS News and Press, Cerus Corporation From 08/04/21

Image source: The Motley Fool. Cerus Corporation (NASDAQ: CERS) Q2 2021 Earnings Call Aug 3, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Cerus Corporation (CERS) Q2 2021 Earnings Call Transcript

Cerus Corporation (CERS) Q2 2021 Earnings Conference Call August 03, 2021 04:30 PM ET Company Participants Matt Notarianni - Senior Director of Investor Relations Obi Greenman - President and Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kevin Green - Chief Financial Offic...

Cerus (NASDAQ:CERS): Q2 GAAP EPS of -$0.09 beats by $0.01. Revenue of $37.76M (+40.7% Y/Y) beats by $11.73M. Product Revenue of $31.5 Million Led by 128% Growth in North America as INTERCEPT Platelet Sales Ramped in the U.S. Increasing 2021 Product Revenue Guidance: Based ...

Highest Quarterly Total and Product Revenue in Company History Total Revenue of $37.8 Million Grew 41% in Second Quarter Product Revenue of $31.5 Million Led by 128% Growth in North America as INTERCEPT Platelet Sales Ramped in the U.S. Full-Year 2021 Product R...

NTAP provides incremental reimbursement under CMS’ IPPS for IFC Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted a new technology add-on payment (NTAP) for INTERCEPT Fibrinogen Complex within...

Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2021 financial results will be released on Tuesday, August 3, 2021, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management w...

Cerus Corporation (NASDAQ:CERS) traded at a new 52-week low today of $4.71. So far today approximately 223,000 shares have been exchanged, as compared to an average 30-day volume of 1.7 million shares. Cerus Corp is a biomedical products company focused in the field of blood transfusion ...

Cerus Corporation (NASDAQ:CERS) traded at a new 52-week low today of $4.97. Approximately 223,000 shares have changed hands today, as compared to an average 30-day volume of 1.7 million shares. Cerus Corp is a biomedical products company focused in the field of blood transfusion safety. ...

The Swiss Red Cross is a global pioneer in the nationwide adoption of Cerus’ pathogen inactivation technology Cerus Corporation (Nasdaq: CERS), a company solely dedicated to safeguarding the global blood supply, and the Transfusion Service of the Swiss Red Cross (Blut...

Cerus Corporation (NASDAQ:CERS) traded today at a new 52-week low of $5.11. Approximately 223,000 shares have changed hands today, as compared to an average 30-day volume of 1.6 million shares. Cerus Corp is a biomedical products company focused in the field of blood transfusion safety. ...